ArteraAI Validates Prognostic Model in Advanced Prostate Cancer
ArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read MorePosted by Andy Lundin | Oct 16, 2023 | Prostate |
ArteraAI will present data demonstrating the successful validation of its prognostic model in advanced prostate cancer.
Read MorePosted by Andy Lundin | Oct 11, 2023 | Cancer, Digital Pathology |
CorePlus, a high complexity anatomic pathology laboratory, diagnosed over 10,000 cases using Ibex’s AI-powered cancer diagnostics platform.
Read MorePosted by Andy Lundin | Oct 10, 2023 | Cancer |
The genomic profiling test is approved to identify patients with solid tumors with RET gene fusions who may benefit from Retevmo treatment.
Read MorePosted by Andy Lundin | Oct 9, 2023 | Prostate |
Researchers developed a patent-pending method and algorithm to predict prostate cancer recurrence in patients treated by radiation therapy.
Read MorePosted by Andy Lundin | Oct 4, 2023 | Cancer, Company News |
EValuate Diagnostics aims to make tests that detect cancer early, and will market a system for the capture of extracellular vesicles.
Read More